Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa
Phase 2
Terminated
- Conditions
- Dystrophic Epidermolysis BullosaJunctional Epidermolysis Bullosa
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-07-05
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Lenus Therapeutics, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT03578029
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸SUNY Downstate Medical Center, Brooklyn, New York, United States
🇺🇸Northwestern University, Evanston, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath